Skip to content
Bacterial vaginosis (BV) is the most common vaginal infection among women of reproductive age. This disease is associated with serious adverse health outcomes. According to current treatment protocols, women are prescribed antibiotics. However, more than half of patients experience a recurrence of vaginosis within just three months. Australian researchers from Monash University and the Melbourne Sexual Health Centre claim that the results of their landmark study hold a key to reducing the recurrence rate of BV among women.
Bacterial Vaginosis and Its Impact on Women’s Reproductive System
Bacterial vaginosis is defined as an imbalance of the vaginal microbiota, associated with the overgrowth of primarily anaerobic bacteria in the vagina. This imbalance poses significant risks, including infertility, premature birth, and an increased risk of neonatal death. Furthermore, BV raises the likelihood of contracting other sexually transmitted infections (STIs). It is estimated that approximately 23-29% of women worldwide suffer from vaginosis, with this figure rising in various regions.
Bacterial Vaginosis or Vaginitis?
It is important to distinguish between bacterial vaginosis and vaginitis. While both conditions cause inflammation in the vagina, BV results from a specific imbalance in the normal bacterial flora. In contrast, vaginitis can be caused by a variety of factors, including infections (like STIs), allergic reactions, certain surgical procedures, or trauma. BV is the most common form and typically presents with unusual vaginal discharge, an unpleasant odor, and irritation. However, some women may be asymptomatic.
For more details on vaginitis, see our Encyclopedia article.
The Role of Men in the Transmission of BV
In medical guidelines, BV is typically not classified as a sexually transmitted disease (STD). However, its association with sexual behavior, including changes in sexual partners and no condom use, leads many researchers to suspect that BV can indeed be transmitted.
Previous treatment trials involving male partners did not show an increased recovery rate, which was interpreted as evidence against sexual transmission.
However, these studies had design limitations, and none used a combination of oral and topical antibiotics to adequately clear BV bacteria in men, especially from the penile-skin site.
Professor Catriona Bradshaw, lead author, Monash University
According to Dr. Bradshaw, a single dose of oral antibiotics is insufficient to cleanse the male genitalia of microorganisms associated with bacterial vaginosis.
This is why researchers conducted a randomized controlled trial to determine whether simultaneous oral and local antimicrobial treatment of both partners reduces the risk of recurrence in women undergoing first-line BV therapy, compared to treating only the woman.
A Revolutionary Approach to Treatment
The study involved 164 couples in monogamous relationships, where the woman had BV. For the first time, researchers tested the hypothesis that treating both sexual partners would lead to better outcomes than the traditional method of treating only the woman. The results were striking: after treating both partners simultaneously, the recurrence rate of BV in women decreased by 50%. In fact, the study was terminated early due to the high efficacy of the dual therapy approach.
This successful intervention is relatively cheap and short and has the potential for the first time to not only improve BV cure for women, but opens up exciting new opportunities for BV prevention, and prevention of the serious complications associated with BV.
Professor Catriona Bradshaw
The results of this study could change the approach to BV treatment worldwide. The Melbourne Sexual Health Centre has already started using partner treatment in its clinical practice and encourages other institutions to follow their example. This study also provides important insights into the need for further research to identify the specific bacteria responsible for BV.
Specialists at the Lior Medical Center remind patients of the importance of barrier contraception during sex with a new partner. Additionally, if you experience discomfort in the vagina or changes in discharge, it is crucial to refrain from sexual activity and consult a specialist. For more information and to schedule an appointment, call +380 73 200 6198 or reach us via Telegram.
